A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2028

Conditions
Ewing Sarcoma
Interventions
DRUG

KC1036

For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.

Trial Locations (1)

100045

RECRUITING

Beijing Children's Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY

NCT06564272 - A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma | Biotech Hunter | Biotech Hunter